Discover our strategy

Redefining Regeneration

Join Maxonis' management for an investor webinar introducing the company’s differentiated approach to peripheral nerve repair, spinal cord injury, and more broadly, regenerative medicine.

The discussion will provide an overview of the significant unmet need in peripheral nerve injury, the limitations of existing treatment options, and how Maxonis’ lead asset, LDP-916, is designed to support functional nerve regeneration through a biologically active approach.

Management will also discuss the company’s strategic vision, commercial opportunity, and key upcoming milestones, followed by a live Q&A session.

May 28th, 2026

11:30 AM ET - 12:00 PM ET

Why Investors Choose Maxonis

First-in-class Nerve Regeneration Platform
LDP-916 is a peptide–hydrogel therapy designed to actively regenerate nerve tissue rather than simply bridge damaged nerves.
Large Unmet Markets in PNI and SCI
Targeting peripheral nerve injury and spinal cord injury addresses areas where current treatments often fail to restore meaningful
function.
Strong Preclinical Accomplishments
Encouraging animal-model results show functional recovery signals across PNI and SCI programs.
Scientific and Commercial Leadership
The team combines nerve-repair science, biomaterials innovation, and prior health-tech commercialization experience.

Ready to Learn More?

Join Maxonis on May 28, 2026 for an engaging conversation with the company's CEO, Itay Itzhaky, and the scientific co-founder, Professor Shimon Rochkind.

Disclaimer

All investing is subject to risk, including the possible loss of the money you invest.

These statements should not be construed as, (i) an offer to sell or a solicitation of an offer to buy any security, or (ii) investment, tax, legal, or other advice. Any such offer or solicitation will be made only by means of an offering document that meets all applicable legal requirements.

Statements contained herein that are not historical facts, including statements regarding objectives, strategies, and performance targets, may constitute forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, and actual results may differ materially from those expressed or implied in such statements. Past performance is not necessarily indicative of, and cannot be relied upon as a guarantee of, future results. Investors should consult their own advisors with respect to any investment decision.

Terms & Use